-
In a prospective cohort study, women with endometriomas (> 2 cm) were found to have a decrease in ovarian reserve parameters compared to healthy controls 1 and 6 months after the endometriomas were removed.
-
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.
-
Although annual screening mammography did increase the detection rate of non-palpable tumors, it did not reduce mortality from breast cancer over 25 years of follow-up.
-
Compared to cyclic use, a drospirenone-containing oral contraceptive pill used in a continuous fashion after the removal of an endometrioma is associated with a reduction in dysmenorrhea, non-menstrual pelvic pain, and reoccurrence of endometrioma formation.
-
-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
-
A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
-
Using the SEER database, this report examined 1926 patients aged ≥ 70 years who were diagnosed with limited-stage small cell lung cancer between 1988 and 1997.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.
-
For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
